Resource Center

www.lls.org/resourcecenter

More to Explore - Information About Blood Cancers for Patients, Families and Healthcare Professionals

The Word:

donate

June 9, 2014 - Update on PTCL

Your order contains  item(s)  View Order

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: June 9, 2014
Time: 1:00 p.m. - 2:00 p.m. ET
Location: Telephone/Web
View: Program Slides
Read: Transcript
Listen: Presentation | Q&A Session

Topics Covered

  • How peripheral T-cell lymphoma (PTCL) is diagnosed
  • PTCL subtypes
  • Treatments for newly diagnosed and relapsed/refractory patients
  • Clinical trials and novel treatment options for PTCL patients
  • Side effects management for PTCL
  • The importance of open communication with your healthcare team

Speaker

Lauren C. Pinter-Brown, MD, FACP
Clinical Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, CA

Questions Asked by the Peripheral T-cell Lymphoma Community:

  • Can peripheral T-cell-NOS (not otherwise specified) come back indolent?
  • I was wondering how to find a physician that has treated people with subcutaneous panniculitis-like T-cell lymphoma? 
  • Is there anything that can help with fatigue and itching?
  • Are there vaccine therapy trials for PTCL?
  • At what point do you recommend a clinical trial? Should patients try standard or proven methods first?
  • Does malignant mastocytosis have any relationship to peripheral T-cell lymphoma?
  • Is there a replacement or successor for Ontak® (denileukin diftitox) since it was withdrawn at the end of 2013?
  • Will Revlimid® (lenalidomide) be used for any of the peripheral T-cell lymphomas?
  • Can you comment on the role of autologous and allogeneic stem cell transplants, and also the rationale for having an autologous transplant followed by an allogeneic transplant?
  • I've heard that brentuximab vedotin is being studied in children with relapsed systemic anaplastic large-cell lymphoma. Are there any results from these studies?
  • Are mycosis fungoides and Sézary syndrome the same?
  • Are there any drug interactions to look for with brentuximab vedotin?
  • What are some treatment options for CD30-positive ALCL other than methotrexate?
  • Radiation is listed as a treatment option. Is that only during transplant or is it sometimes used alone?
  • Are there specific treatments for recurring enteropathy-associated T-cell lymphoma (EATL) type II?
  • How often should a patient in remission from anaplastic large T-cell lymphoma be getting positron emission tomography (PET) or computed tomography (CT) scans?
  • Since PTCL is uncommon, are there resources to help me connect with others who can relate to what I'm going through?
  • I'm on pralatrexate for PTCL and was wondering if I can get the shingles vaccine?

Sponsors and Supporters

This program is sponsored by The Leukemia & Lymphoma Society and supported by a grant from Celgene Corporation.

last updated on Thursday, September 11, 2014
btn_sharethis